Response to letter to the editor “AML and MDS associated with PARP inhibitor treatment of ovarian cancer”

Volume 171, April 2023, Pages 164-165

Author links open overlay panelDavid M. O'Malley a, Jonathan A. Ledermann b, Robert L. Coleman cShow morePrevious article in issueNext article in issue

More from this channel

Response to letter to the editor “AML and MDS associated with PARP inhibitor treatment of ovarian cancer”

留言 (0)